跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03631615
NCT03631615Unknown2 期

A Phase II Study of Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in the Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2018年8月20日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
36
试验地点
1
主要终点
pathological complete remission (pCR) rate of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210) in patients with locally advanced proximal stomach adenocarcinoma.
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

  1. Target population: patients with resectable locally advanced proximal (including gastroesophageal junction, fundus and upper body) stomach adenocarcinoma (cT3-4aN+M0).
  2. Primary objective: pathological complete remission (pCR) rate of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210) in patients with locally advanced proximal stomach adenocarcinoma.

Secondary objectives:

  1. pathological remission rate (pRR) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
  2. objective response rate (ORR) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
  3. progression free survival (PFS)/ overall survival (OS) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
  4. safety of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)

3.Trial design: This is a monocenter, single arm, phase II study to evaluate the efficacy and safety of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210) in patients with locally advanced proximal stomach adenocarcinoma.

4.Treatment plan:

Patients will be given the perioperative treatment as below once recruited:

  1. induction chemotherapy (3w): one cycle of XELOX regimen (capecitabine 1000 mg/m2 bid*14d + oxaliplatin 130mg/m2, d1, Q21d);
  2. within one week after the induction, concurrent chemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas, total dose:45Gy/25d, 1.8Gy/d, capecitabine (850 mg/m2, bid, po) will be given during radiotherapy as sensitizer.
  3. consolidation chemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen (capecitabine 1000 mg/m2 bid*14d + oxaliplatin 130mg/m2, d1, Q21d); From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given（200mg, iv, q3w).

Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.

Adjuvant chemo: We advice starting 4 cycles of XELOX regimen (capecitabine 1000 mg/m2 bid*14d + oxaliplatin 130mg/m2, d1, Q21d) in 4-6w after surgery.

5.Number of subjects: 36 patients. Number of centers: 1 sites ( Fudan University Affiliated Zhongshan Hospital, which has high volume of gastric operations in China, more than 500 per year).

详细描述

Backgrounds:

SHR-1210 is a PD-1 antibody developed by Jiangsu Heng Rui Medicine Co. Nowadays, fifteen clinical trials of this drug have been conducted in patients with different types of advanced malignant tumor, including one combined with radiotherapy and three combined with chemotherapy. Until now, SHR-1210 has exhibited favorable safety in recruited patients. Incidence rate of SAE is only 1%.

Several big scale clinical research like POET, RTOG 9904 and TOPGEAR have proofed the efficacy and safety of neoadjuvant chemoradiation in treating locally advanced GEJ cancer or gastric cancer.

Study design:

This clinical trial will be conducted under Simon's optimal two-stage design. The first stage needs 15 participants, if ≥1 participants acquire remission, then the study will move on to the second stage and enroll the rest 21 participants. The total sample size will be 36 patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •histologically documented gastric adenocarcinoma.
  • •primary lesion is in proximal stomach, including gastroesophageal junction, fundus and upper body.
  • •clinically diagnosed stage T3-4aN+M0 according to ultrasound endoscopy or enhanced CT/MRI scan.
  • •at least one evaluable lesion in abdominal CT/MRI according to RESIST 1.1 is required.
  • •surgeons participating in this study consider the lesion a resectable one.
  • •Karnofsky score≥
  • •Physical condition and adequate organ function to ensure the success of abdominal surgery.
  • •Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥90g/L.
  • •Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN in the absence of liver metastases, or < 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L.
  • •Adequate renal function: Serum creatinine ≤ 1.5 x ULN, and creatinine clearance ≥ 60 ml/min.
  • •Adequate coagulation function: INR/PT≤ 1.5 x ULN, aPTT≤ 1.5 x ULN.
  • •No serious concomitant disease that will threaten the survival of patients to less than 5 years.
  • •Male or female. Age ≥ 18 years and ≤75 years.
  • •Written (signed) informed consent.
  • •Good compliance with the study procedures, including lab and auxiliary examination and treatment.
  • •Female patients should not be pregnant or breast feeding.
  • •Agree to take contraception measures during treatment and in 120 days after last dose of SHR-1210 or in 180 days after last dose of chemo.

排除标准

  • •patients with distant metastasis or unresectable primary lesion.
  • •patients with T1, T2 lesion according to CT/MRI or ultrasound endoscopy.
  • •history of chemo, radiation, immune therapy or radical resection for the stomach adenocarcinoma, except steroids.
  • •patients with active autoimmune disease or history of refractory autoimmune disease.
  • •patients with active malignant tumor in recent 2 years, except the tumor studied in this research or cured locally tumor like resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ.
  • •uncontrollable pleural effusion, pericardial effusion, or ascites in 2 weeks before recruitment.
  • •patients who have digestive tract bleeding in 2 weeks before recruitment or with high risk of bleeding.
  • •perforation / fistula of GI tract in 6 months before recruitment.
  • •patients with upper GI tract obstruction or functional abnormality or malabsorption syndrome, which can affect absorption of capecitabine.
  • •losing over 20% body weight in 2 months before recruitment.
  • •pulmonary disease history: interstitial pulmonary disease, non-infective pneumonitis, pulmonary fibrosis, acute pulmonary disease.
  • •uncontrollable systemic diseases, including diabetes, hypertension, etc.
  • •severe chronic or active infections in need of systemic antibacterial, antifungal, or antiviral treatment, including TB or HIV, etc.
  • •patients with untreated chronic hepatitis B or HBV DNA over 500 IU/ml or positive HCV RNA.
  • •patients with any cardiovascular risk factors below:
  • •cardiac chest pain occurring in 28 days before recruitment, defined as moderate pain that limits daily activity.
  • •pulmonary embolism with symptoms occurring in 28 days before recruitment.
  • •acute myocardial infarction occurring in 6 months before recruitment.
  • •any history of heart failure reaching grade 3/4 of NYHA in 6 months before recruitment.
  • •ventricular arrhythmias of Grade 2 or grater in 6 months before recruitment, or accompanied by supraventricular tachyarrhythmias requiring medical treatment.
  • •cerebrovascular accident within 6 months before recruitment.
  • •patients with peripheral neuropathy NCI CTC AE grade 1, except those with only deep tendon reflex disappearing.
  • •moderate or severe renal injury [creatinine clearance rate≤50 ml/min (according to Cockroft & Gault equation)], or Scr>ULN.
  • •dipyrimidine dehydrogenase (DPD) deficiency.
  • •allergic to any drug in this study.
  • •history of allogeneic stem cell transplantation or organ transplantation.
  • •use of steroids (dosage>10mg/d prednisone) or other systemic immune suppressive therapy in 14 days before recruitment, except patients treated with regimens below: a. steroids for hormone replacement (dosage>10mg/d prednisone); b. steroids for local application with little systemic absorption; c. short -term (≤ 7 days) steroids for preventing allergy or vomiting.
  • •vaccinated with live vaccine in 4 weeks before recruitment.
  • •receiving immune (interleukin, interferon, thymin) treatment or treatment of other trials in 28 days before recruitment.
  • •receiving palliative radiation in 14 days before recruitment.
  • •history of anti PD-1, PD-L1, PD-L2 or any other specific T cell co-stimulation or checkpoint pathway targeted treatment.
  • •receiving operation in 28 days before recruitment, only if the operation is a minimally invasive one e.g. PICC.
  • •for patients with uncontrolled epilepsy, CNS diseases or history of mental disorder, researchers should evaluate whether their diseases will impede their signing of informed consent or compliance of treatment.
  • •existing of potential situation which will impede drug administration or affect toxicity analysis or alcohol/ drug abuse.

研究组 & 干预措施

Neoadjuvant therpy

Experimental

neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)

干预措施: Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210) (Drug)

结局指标

主要结局

pathological complete remission (pCR) rate of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210) in patients with locally advanced proximal stomach adenocarcinoma.

时间窗: 5 months after the last subject participating in

rate of patients with no residual tumor lesion (Grade 3) in surgical specimen

次要结局

  • overall survival (OS) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)(36 months after the last subject participating in)
  • objective response rate (ORR) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)(36 months after the last subject participating in)
  • safety of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)(1 month after the last date of treatment)
  • pathological remission rate (pRR) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)(5 months after the last subject participating in)
  • progression free survival (PFS) of neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)(36 months after the last subject participating in)

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tianshu Liu

Director of Oncology Department

Shanghai Zhongshan Hospital

研究点 (1)

Loading locations...

相似试验

已完成
2 期
Neoadjuvant Immunotherapy for Resectable Gastric CancerGastric Cancer
NCT03878472Qilu Hospital of Shandong University25
已完成
2 期
Phase II study of neoadjuvant chemoradiation therapy with cisplatin plus fluorouracil for esophageal cancerEsophageal cancer
JPRN-jRCT1041180004Maeda Osamu12
已完成
不适用
Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer PatientsBreast Cancer Female
NCT06631066National Cancer Institute, Egypt160
终止
不适用
Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression AssaysRectal AdenocarcinomaAnal AdenocarcinomaAnal Squamous Cell Carcinoma
NCT02407561Castle Biosciences Incorporated3
已完成
不适用
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer PatientsAdenocarcinomaEffects of ChemotherapySurgeryGastrointestinal NeoplasmsGastric Cancer
NCT02454647Clinica Universidad de Navarra, Universidad de Navarra46